article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

article thumbnail

Biosimilars Market Set for Biggest Year Yet in 2023

PM360

The entirety of healthcare stakeholders is watching the biosimilars market closely because LOE events, particularly the Humira LOE, is likely to impact payers, providers, patients, and pharmaceutical manufacturers—both brand and biosimilar—and potentially society as a whole given the current controversy over rising drug prices.